Drug Registration and Acceptance

Drug Name

Exact

Active Ingredient

Acceptance No.

Manufacturers

Acceptance Date

Status Date

Classification

Review Status

Drug Type

Submission

Evaluation Conclusion

ATC Category

Special Approval Varieties

Task Type

Major Special Varieties

Sequence No.

Stock Code

Visualized Analysis Export Evaluation Conclusion Evaluation Progress

Acceptance No.	Drug Name	Active Ingredient	Dosage Form	Classification	Submission	Acceptance Date	Manufacturers	Manufacturers	Review Status	View
JXSS2200005	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products(3.1)	Import Drug Application	2022-01-26				view
JYSB2101162	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2021-11-10				view
JYSB2300183	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2023-10-26				view
JYSB2200143	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2022-08-08		Bayer Healthcare LLC		view
JYSB2200065	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2022-04-08		Novo Nordisk A/S		view
JYSB2200093	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2022-06-09				view
JYSB1200214	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2012-08-27	拜耳医药保健有限公司	Bayer Healthcare Company Ltd	Approval Completed-Pending Certificated	view
JYSB2400049	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2024-03-07				view
CXSS2200014	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products(3.4)	New Drug Application	2022-02-18		Chengdu Rongsheng Pharmaceuticals Co Ltd		view
JYSB2101081	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2021-07-05		Bayer Healthcare LLC		view
JYSB2300035	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2023-02-23		Bayer Healthcare LLC		view
JYSB2200092	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2022-06-09				view
JYSB2200164	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2022-08-24		Bayer Healthcare LLC		view
JYSB2200095	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2022-06-09				view
JYSZ2200030	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	License Renew	2022-06-29				view
JYSB2200063	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2022-04-08		Novo Nordisk A/S		view
JYSB2200066	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2022-04-08		Novo Nordisk A/S		view
JYSZ2100534	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	License Renew	2021-12-17				view
JYSB2400051	注射用重组人凝血因子VIII	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2024-03-07				view
JYSB2200064	注射用重组人凝血因子Ⅷ	Recombinant Coagulation Factor Ⅷ	Lyophilized	Biological Products	Supplementary Application	2022-04-08		Novo Nordisk A/S		view